Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mo-Rez vs chemotherapy in endometrial cancer after platinum and immunotherapy
jRCT2011260006Phase 3Recruiting
- Sponsor
- GSK
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mocertatug rezetecan in endometrial cancer (EC) (2 arms), sponsored by GSK. Primary endpoints: Objective response rate (ORR) by BICR and Progression-free survival (PFS) by BICR. Started Jun 2026; status: recruiting.
02
Drugs
mocertatug rezetecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2011260006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011260006.